ELVN
Enliven Therapeutics, Inc.
Healthcare — Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Price History
Fundamentals
| Market Cap | $3.48B |
| P/E Ratio (TTM) | - |
| Forward P/E | -22.57 |
| EPS (TTM) | $-1.64 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -26.64% |
| Debt/Equity | 0.07 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $65.11 |
| Analysts | 9 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 73.4 |
| Beta | 0.40 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $52.39 |
| 52-Week Low | $14.79 |
| 50-Day Avg | $42.32 |
| 200-Day Avg | $29.39 |
| Avg Volume | $1.35M |
| Volume | 995.8K |
Performance Analysis
BULLISHELVN shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:07 UTC
Back to Screener Export Report